Silverman, Stuart
Langdahl, Bente L.
Fujiwara, Saeko
Saag, Ken
Napoli, Nicola
Soen, Satoshi
Enomoto, Hiroyuki
Melby, Thomas E.
Disch, Damon P.
Marin, Fernando
Krege, John H.
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 8 May 2018
Accepted: 12 October 2018
First Online: 20 October 2018
Compliance with Ethical Standards
:
: S.S. is on the Speaker’s Bureau and is a consultant for and has received research support from Eli Lilly and Co.; K.S. has received consultant fees and has research Grants from Eli Lilly and Co.; B.L.L. has received fees for serving on advisory boards, speaking at symposia, and has received research grants from Eli Lilly and Co. Amgen, UCB, Merck, and Novo Nordisk; NN has received consultant and speaker fees from Eli Lilly and Co.; S.F. and S.S. have nothing to declare; T.E.M. is an employee of Syneos Health under contract to Eli Lilly and Co.; D.P.D., F.M., H.E., and J.H.K. are employees of Eli Lilly and Co.
: The studies analyzed herein were approved by local ethics committees or review boards, depending on local requirements, and were conducted in compliance with all applicable laws, regulations and guidelines.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual patients included in the study.